NCT03233711 2026-03-18
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
National Cancer Institute (NCI)
Phase 3 Active not recruiting
Clinical Trials
5 trialsNCT04929028 2026-03-18
Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT04166318 2026-03-02
Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study
Eastern Cooperative Oncology Group
Phase 2 Active not recruiting
NCT07407647 2026-02-12
Vaginal DHEA to Improve Vaginal Health After Radiation for Women With Gynecologic, Anal or Rectal Cancer
Ohio State University Comprehensive Cancer Center
Phase 2 Recruiting
NCT02408861 2026-01-21
Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 1 Terminated